Moteur de recherche d’entreprises européennes
Financement de l’UE (2 499 991 €) : Dencatistat, un inhibiteur de CTPS1 de première classe, agnostique tumoral et administrable par voie orale, pour traiter les tumeurs gynécologiques Hor 01/06/2026 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Dencatistat, un inhibiteur de CTPS1 de première classe, agnostique tumoral et administrable par voie orale, pour traiter les tumeurs gynécologiques
Step Pharma is developing dencatistat (STP938), a first-in-class CTPS1 inhibitor that selectively targets CTPS2-null cancers, where tumour cells rely exclusively on CTPS1 for DNA synthesis. This represents a novel tumour-agnostic precision medicine approach that spares healthy tissue, reduces toxicity, and is suitable for oral administration. The current project focuses on advancing dencatistat in gynaecologic cancers, particularly platinum-resistant/refractory ovarian and endometrial tumours, which remain underserved despite high incidence and poor prognosis. The proposal will deliver a Phase 1b clinical trial in 10 biomarker-selected endometrial cancer patients to establish safety and early efficacy, using a validated CTPS2-loss assay. This trial follows a Phase 1a dose-escalation study already underway in ovarian cancer. If successful, a Phase 2 study will be launched with two cohorts (40 biomarker-positive, 40 biomarker-negative) to validate the predictive power of CTPS2-loss and support broader solid tumour expansion. This biomarker-guided strategy will help identify patients most likely to benefit, ensuring cost-efficient clinical development and better outcomes. The EIC grant (€2.5M) will fund critical Phase 1b activities, including patient recruitment, biomarker screening, and regulatory preparation. The requested equity (€10M) will enable Phase 2 execution across ovarian and endometrial cancers. While €37.7M in Series C1 funding has been secured for the ovarian trials, EIC support is essential to unlock the remaining €25M (Series C2) to include the endometrial trial and avoid critical delays in development. This project will lay the foundation for a European-led gynaecologic oncology franchise, with broader application across CTPS2-null solid tumours.
| Step Pharma | 2 499 991 € |
https://cordis.europa.eu/project/id/101297026
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Step Pharma SAS, Paris.
